Lexence advised/assisted the shareholders in Yxion, including Antea Participaties, on the sale of their stake in Yxion to Normec

Lexence advised/assisted the shareholders in Yxion, including Antea Participaties, on the sale of their stake in Yxion to Normec.

Yxion is a consultancy firm for the Pharma, Biotech, Food and Medical Devices industries. Yxion employs around 100 passionate people who are committed to improving people’s health and well-being. The company provides a wide range of compliance consultancy services to support clients in the design, implementation and operation of critical systems, processes and projects. These services are divided into three focus areas: Commissioning and Qualification, Engineering and Project Management, and Quality Assurance.

Normec, founded in 2016 by Joep Bruins, is a leading European provider of Testing, Inspection, Certification and Compliance (TICC) services, with more than 5,000 employees across six European countries. Through the acquisition of Yxion, Normec continues its acquisition strategy in Europe, now also seeking expansion opportunities in the United States.

Yxion was a participation of Antea VI and VII since December 2015. Both parties are extremely pleased with the exit to Normec.

Alex van den Berkt, CEO of Yxion: “Yxion has invested heavily in knowledge and the development of our team in recent years and is now ready for the next step. We are proud to join Normec, an ambitious and growth-oriented organisation already active in our segment. We are confident that our partnership with Normec will bring additional value and benefits to our customers.”
Pieter Wilde, partner at Antea, says: “Yxion has experienced an exceptionally positive development in recent years, which made the company ready for this next step. We are pleased to have been able to support Yxion in its growth and wish the team a successful future as part of Normec.”

The Lexence team consisted of: Kevin Beukeveld, Anne Smit Sibinga, Nicky Spaan and Wouter Koppejan.